Shanu Modi, MD, on Low HER2-Expressing Breast Cancer: Updated Trial Findings
2018 San Antonio Breast Cancer SymposiumShanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings from a large phase I study on trastuzumab deruxtecan in patients with low HER2-expressing breast cancer (Abstract P6-17-02).
Related Videos
Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018: Expert Perspective
Roisin M. Connolly, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses clinical trials during the past year on studies on CDK and PI3K inhibitors in e...
Zaida Morante, MD, on Triple-Negative Breast Cancer: Delaying Adjuvant Chemotherapy
Zaida Morante, MD, of the Instituto Nacional de Enfermedades Neoplasicas, discusses retrospective study findings showing the importance of starting adjuvant chemotherapy for people...
Laura S. Dominici, MD, on Young Women With Breast Cancer: Local Therapy and Quality of Life
Laura S. Dominici, MD, of the Dana-Farber Cancer Institute, discusses the lower quality-of-life scores seen after unilateral or bilateral mastectomy compared with breast-conserving...
Kathryn J. Ruddy, MD, MPH, on Breast Cancer and Quality of Life: Expert Perspective
Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic, summarizes a special spotlight session that included discussion of interventions to improve quality of life and the importance of lif...
Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care
Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse ...
